November 18, 2024

SPT Labtech brings the power of miniaturization to more genomics researchers with mosquito® Gen3

SPT Labtech brings the power of miniaturization to more genomics researchers with mosquito® Gen3

This new instrument delivers automated true positive displacement technology in an exceptionally compact footprint

Cambridge, UK SPT Labtech, a global leader in the design, development and manufacture of automated instrumentation and consumables for life science applications, has expanded its nanoliter liquid handling portfolio with the launch of mosquito Gen3. As the most compact and accessible model of the mosquito range, this new instrument brings next-generation sequencing (NGS) cost savings to more laboratories by lowering the barrier to advanced miniaturization technology.

mosquito Gen3 delivers accurate and precise multi-channel pipetting from 500 nL to 5 µL, with rapid plate-to-plate motion across three available deck positions and a small benchtop footprint[PL1] . Its use of individual pre-sterilized micropipettes eliminates the risk of cross-contamination, ensuring data and research integrity. Developed in collaboration with leading scientists, mosquito software enables quick method implementation and sharing, facilitating miniaturization in novel application areas.

For laboratories requiring higher throughput and greater walkaway capacity, mosquito HV genomics offers the same accuracy and volume range, with additional two deck positions.

mosquito technology has transformed genomics workflows by significantly reducing reagent consumption and scaling down reaction volumes without compromising data quality. Unlike traditional air displacement technology, mosquito’s true positive displacement technology maintains accuracy across all liquid classes and environmental conditions. This technology has enabled miniaturization of over 40 NGS kits, including industry standards such as Illumina Nextera XT, Illumina DNA Prep, NEBNext® Ultra™ II and Takara SMART-Seq chemistries. 

“Automated liquid handling has become essential for genomics labs to meet the demands of modern research. Miniaturization is a particularly advantageous technique that allows for substantial cost savings and maximum reach of precious samples and reagents. We’re lowering the cost barrier to miniaturization with mosquito Gen3, enabling more researchers to experience its benefits. Our expanded mosquito portfolio offers low-volume liquid handling solutions tailored to diverse laboratory resources and needs,” says Kamila Koprowska, Product Manager, mosquito genomics at SPT Labtech.

Contact

Carey Rooks, Head of Brand and Communications, SPT Labtech: marketing@sptlabtech.com

About SPT Labtech

SPT Labtech makes products that transform the way scientists work. For nearly two decades, our expert scientists, engineers, and business innovators have created innovative solutions for liquid handling, sample preparation and management that help accelerate research and make a real difference to human health. We work collaboratively with our customers, building trusted relationships that enable us to deliver exceptional, personalized experiences designed for real world challenges in the lab. For more information, please visit: www.sptlabtech.com

Follow SPT Labtech on Twitter @SPTLabtech and LinkedIn @SPT Labtech

Our latest News

discover more
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, 2026 — VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven computational partner for modern […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp